Today’s Budget announcement included confirmation that the Medicines and Healthcare products Regulatory Agency (MHRA) will receive £10 million extra funding over two years to maximise its use of Brexit freedoms and accelerate patient access to treatments. This will allow, from 2024, the MHRA to introduce new, swift approvals systems, speeding up access to treatments already approved by trusted international partners, including the EU and Japan, and ground-breaking technologies such as cancer vaccines and AI therapeutics for mental health.
Responding to the announcement PAGB Chief Executive, Michelle Riddalls, said:
We are pleased that the Government has announced an additional £10 million extra funding over two years to the Medicines and Healthcare products Regulatory Agency (MHRA) today.
“We are hopeful that this additional funding will help to address the performance issues that have challenged the MHRA following its restructure and that this extra resource will speed up patient access to more treatments in the UK.
